Events2Join
Trial of canakinumab

Trial of canakinumab

Antiinflammatory Therapy with Canakinumab for Atherosclerotic ...

Canakinumab significantly reduced high-sensitivity C-reactive protein levels from baseline, as compared with placebo, without reducing the LDL ...

Clinical Trials Using Canakinumab - NCI

This phase II trial studies the effects of canakinumab in preventing lung cancer in patients who have high-risk pulmonary nodules. Canakinumab is a monoclonal ...

Canakinumab Anti-Inflammatory Thrombosis Outcomes Study

Canakinumab was effective at reducing hsCRP in a dose-response relationship. Canakinumab was effective among those with chronic kidney disease, ...

Canakinumab and Lung Cancer: Intriguing, but Is It Real? - PMC

The relationship between inflammation and cancer is complicated. This editorial calls attention to intriguing findings of the CANTOS trial, ...

Effect of Canakinumab vs Placebo on Survival Without Invasive ...

Finding This randomized clinical trial included 454 patients hospitalized with severe COVID-19 not requiring invasive mechanical ventilation ( ...

Results From the CANOPY-1 Trial | Journal of Clinical Oncology

Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From ...

Novartis provides update on Phase III CANOPY-A study evaluating ...

In the trial, 1,382 patients were randomized 1:1 to canakinumab, 200 mg subcutaneously every three weeks, or matching placebo for up to one year ...

A randomized, placebo-controlled, double-blind trial of ...

Canakinumab treatment of sickle cell anemia did not meet its primary endpoint of a clinically relevant reduction in average daily pain.

Canakinumab as Adjuvant Therapy in Patients With Completely ...

CANOPY-A (ClinicalTrials.gov identifier: NCT03447769) is a phase III, randomized, double-blind, multicenter study of canakinumab versus placebo ...

Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

CANOPY-A did not show a DFS benefit of adding canakinumab after surgery and adjuvant cisplatin-based chemotherapy in patients with resected, ...

Canakinumab for the Treatment of Autoinflammatory Recurrent ...

In this trial, canakinumab was effective in controlling and preventing flares in patients with colchicine-resistant familial Mediterranean fever, mevalonate ...

Single arm phase II trial using canakinumab for the prevention of ...

This phase II trial studies the effects of canakinumab in preventing lung cancer in patients who have high-risk pulmonary nodules.

Novartis provides update on Phase III study evaluating ...

Two Phase III CANOPY trials continue, evaluating canakinumab in first-line and adjuvant settings2,3. Novartis and CANOPY-2 investigators will ...

Adjunctive canakinumab reduces peripheral inflammation markers ...

Blocking Interleukin-1β reduces symptoms in patients with elevated inflammation. Abstract. Background. Clinical trials of anti-inflammatories in schizophrenia ...

Repositioning canakinumab for non-small cell lung cancer ... - Nature

Observations from the CANTOS trial led Novartis to launch the CANOPY study programme, including three large-scale randomised Phase III clinical ...

Effect of interleukin-1β inhibition with canakinumab on incident lung ...

The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) was a randomised, double-blind, placebo-controlled trial of 10 061 patients ...

Anti-Inflammatory Therapy With Canakinumab for the Prevention of ...

This study represents the first time a targeted anti-inflammatory therapy has reduced hospitalization for heart failure in at-risk patients.

Double-blind randomized proof-of-concept trial of canakinumab in ...

Our aim was to perform a proof of concept trial with canakinumab, a monoclonal antibody to interleukin-1β, in patients with COVID-19, myocardial injury, and ...

TET2-Driven Clonal Hematopoiesis and Response to Canakinumab

Findings In this exploratory genomic substudy of a randomized clinical trial, compared with published cardiovascular disease cohorts, CHIP was ...

Canakinumab in patients with COVID-19 and type 2 diabetes

Study Design. CanCovDia was a multicentre, 1:1 randomised, double-blind, placebo-controlled trial to evaluate the effects of treatment with ...